Fusion Antibodies PLC Update on R&D programme (4285Z)
18 Settembre 2020 - 10:31AM
UK Regulatory
TIDMFAB
RNS Number : 4285Z
Fusion Antibodies PLC
18 September 2020
Fusion Antibodies plc
("Fusion" or the "Company")
Update on R&D programme
Progress with coronavirus antigen and Library
Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical
antibody discovery, engineering and supply for both therapeutic
drug and diagnostic applications, provides an update on the
Company's research and development programme.
The Company's proof-of-concept work on the Mammalian Antibody
Library Discovery Platform (the "Library") continues to progress
according to plan. The Company has made progress on the design,
expression and validation of SARS-CoV-2 proteins, commonly known as
Coronavirus spike proteins. These antigens have been tested by
external partners against patient blood samples and show a 100%
correlation with results from a leading certified benchmark
test.
The Company's extensive antigen manufacturing capabilities means
that Fusion has been able to express high-purity antigens on a
commercially viable scale for the development of diagnostic tests.
The Company is now offering these antigens on a commercial basis to
companies and researchers worldwide. Unlike the PCR tests that are
currently being used to identify the presence of COVID-19, Fusion's
antigens are able to confirm recent past infections and determine
levels of neutralising antibodies to COVID-19. This could be
invaluable for disease modelling and public health policy, as it
will assist in the determination of true transmission rates and
case fatality rates.
The Company has commenced use of these antigens to interrogate
the Library for SARS-CoV-2 neutralising antibodies with a view to
providing these as potential prophylactic and therapeutic
candidates.
Dr Richard Buick, CTO of Fusion Antibodies, said: "We are
committed to developing the highest quality reagents to be used in
the fight against COVID-19. Recent lab studies have shown that
results using our antigens correlate 100% with clinical data from
patients infected with SARS-CoV-2. We are using these high quality
antigens to pan our human antibody library for SARS-CoV-2
neutralising antibodies, and we are delighted to now be able to
make these antigens available to companies and researchers around
the world to Test, Track & Trace this disease."
Paul Kerr, CEO of Fusion Antibodies said: "According to the FDA,
antigen tests will play a critical role in the fight against
COVID-19 and like many other companies within the antibody world at
large, we are leveraging our antigen expertise to create multiple
antigens to be used against the COVID-19 pandemic. "
Enquiries:
Fusion Antibodies plc www.fusionantibodies.com
Dr Paul Kerr, Chief Executive Officer Via Walbrook PR
James Fair, Chief Financial Officer
Allenby Capital Limited Tel: +44 (0)20 3328 5656
James Reeve / Asha Chotai (Corporate
Finance)
Tony Quirke (Sales)
Walbrook PR Tel: +44 (0)20 7933 8780 or fusion@walbrookpr.com
Anna Dunphy Mob: +44 (0)7876 741 001
Paul McManus Mob: +44 (0)7980 541 893
About Fusion Antibodies plc
Fusion is a Belfast based contract research organisation ("CRO")
providing a range of antibody engineering services for the
development of antibodies for both therapeutic drug and diagnostic
applications.
The Company's ordinary shares were admitted to trading on AIM on
18 December 2017. Fusion provides a broad range of services in
antibody generation, development, production, characterisation and
optimisation. These services include antigen expression, antibody
production, purification and sequencing, antibody humanisation
using Fusion's proprietary CDRx (TM) platform and the production of
antibody generating stable cell lines to provide material for use
in clinical trials. Since 2012, the Company has successfully
sequenced and expressed over 250 antibodies and successfully
completed over 100 humanisation projects and has an international,
blue-chip client base, which has included eight of the top 10
global pharmaceutical companies by revenue.
The Company was established in 2001 as a spin out from Queen's
University Belfast. The Company's mission is to enable
pharmaceutical and diagnostic companies to develop innovative
products in a timely and cost-effective manner for the benefit of
the global healthcare industry. Fusion Antibodies provides a broad
range of services in antibody generation, development, production,
characterisation and optimisation.
Fusion Antibodies growth strategy is based on combining the
latest technological advances with cutting edge science to deliver
new platforms that will enable Pharma and Biotechs get to the
clinic faster, with the optimal drug candidate and ultimately speed
up the drug development process.
The global monoclonal antibody therapeutics market was valued at
$135.4 billion in 2018 and is forecast to surpass $212.6 billion in
2022, an increase at a CAGR of 12.0 per cent. for the period 2018
to 2022. In 2017, seven of the world's ten top selling drugs were
antibody-based therapeutics with the combined annual sales of these
drugs exceeding $63.2 billion.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
UPDLPMPTMTTBMRM
(END) Dow Jones Newswires
September 18, 2020 04:31 ET (08:31 GMT)
Grafico Azioni Fusion Antibodies (LSE:FAB)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Fusion Antibodies (LSE:FAB)
Storico
Da Apr 2023 a Apr 2024